SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 2nd, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 2nd, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of January 29, 2024, between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
CNS Pharmaceuticals, Inc. Attention: John Climaco 2100 West Loop South, Suite 900 Houston, Texas Dear Mr. Climaco:Placement Agent Agreement • February 2nd, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 2nd, 2024 Company Industry JurisdictionThis letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.”), Maxim Group LLC (“Maxim” and together with A.G.P., the “Placement Agents”) and CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), that the Placement Agents shall serve as the exclusive placement agents for the Company, on a reasonable “best efforts” basis, in connection with the proposed placement (the “Placement”) of (i) shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), (ii) warrants (the “Common Warrants”) to purchase shares of Common Stock (the “Common Warrant Shares”) and (iii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares and Common Warrants, the “Securities”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”). The Securities actually placed by the Placement Agents are referred to herein as the “Placement Agents Securities.” The terms of the Placement shall be m
AMENDMENT TO COMMON STOCK PURCHASE WARRANTSCommon Stock Purchase Warrant Amendment • February 2nd, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 2nd, 2024 Company Industry JurisdictionThis AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of January 29, 2024, by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and _______ (the “Holder”).